PTAB Upholds Corcept Patent For Cushing's Syndrome Drug
The Patent Trial and Appeal Board won't invalidate any claims from a Corcept Therapeutics patent covering the company's flagship Cushing's syndrome medication Korlym....To view the full article, register now.
Already a subscriber? Click here to view full article